Abstract:1, 2, 3, 4, 6-penta-O-galloyl-β-D-glucose (PGG), a naturally occurring hydrolyzable gallotannin, has been shown by us and others to exhibit in vivo anti-cancer effects against prostate and breast cancer xenograft or lung cancer allograft when administrated by i.p injection or oral gavage. However, little is known of its safety for chronic chemoprevention use and virtually nothing is known of its in vivo target proteins. In the present study, we treated C57B6 mice with daily gavage of PGG from 7 weeks of age to 14 weeks of age with dosages of 1 and 2 mg per mouse (40-50 and 80-100mg/kg body weight). The dosage choices were made in reference to the efficacious anti-cancer dose of 20 mg/kg body weight. General health, body weights and food intake of mice were monitored. At necropsy, the organ weights were measured. Proteomic patterns in the prostate were profiled by 2D LC-MALDI-TOF/TOF analysis with iTRAQ labeling. Our results show that neither dose affected feed intake and body weight gain, but the 2 mg dose led to a statistically significant but very minor decrease of the weight of prostate and thymus. Proteome profiling by LC-MALDI-TOF/TOF identified 810 proteins from mouse prostates and 623 of them were identified with >95% confidence. Expression of 56 proteins was significantly modulated by either 1mg or 2mg PGG daily treatment, four different kinds of dose responses of proteins modulated by PGG were observed. Protein quantization results were validated by another mass spectrometry, ESI-Q-TOF. Selected proteins were further validated by Western blots and mRNA level by real-time PCR. The proteome profiles modulated by PGG include suppression of oncoproteins such as fatty acid synthase and induction of tumor suppressor proteins such as glutathione S-transferase M. Overall, the data show protein changes induced by tolerated dosages of PGG in the normal prostate are conducive for cancer chemoprevention. The chemopreventive efficacy of PGG is being evaluated in a primary carcinogenesis model. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2879.

Penta-1,2,3,4,6-O-galloyl-beta-D-glucose Induces P53 and Inhibits STAT3 in Prostate Cancer Cells in Vitro and Suppresses Prostate Xenograft Tumor Growth in Vivo.

Protein Phosphatase-2A is a Target of Epigallocatechin-3-Gallate and Modulates P53-Bak Apoptotic Pathway

Penta-O-Galloyl-Beta-D-Glucose Induces S- and G(1)-Cell Cycle Arrests in Prostate Cancer Cells Targeting Dna Replication and Cyclin D1

Pentagalloylglucose induces autophagy and caspase-independent programmed deaths in human PC-3 and mouse TRAMP-C2 prostate cancer cells.

Pentagalloyl Glucose (PGG) Exhibits Anti-Cancer Activity against Aggressive Prostate Cancer by Modulating the ROR1 Mediated AKT-GSK3β Pathway

Abstract 2879: Proteome Changes in Mouse Prostate Induced by Oral Administration of Penta-O-galloyl-beta-d-glucose (PGG) Suggest Targets for Cancer Chemoprevention

Mouse Prostate Proteome Changes Induced by Oral Pentagalloylglucose Treatment Suggest Targets for Cancer Chemoprevention

1,2,3,4,6-Penta-O-galloyl-β-d-glucose suppresses colon cancer through induction of tumor suppressor

Penta‐1,2,3,4,6‐O‐galloyl‐beta‐D‐glucose Induces Senescence‐like Terminal S‐phase Arrest in Human Hepatoma and Breast Cancer Cells

Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways

Involvement of Autophagy Induction in Penta-1,2,3,4,6-o-galloyl-β-d-glucose-induced Senescence-Like Growth Arrest in Human Cancer Cells.

In vitro anti-hepatocellular carcinogenesis of 1,2,3,4,6-Penta-O-galloyl-β-D-glucose

Anti-metastatic effects of 1,2,3,4,6-Penta-O-galloyl-β-D-glucose in colorectal cancer: Regulation of cathepsin B-mediated extracellular matrix dynamics and epithelial-to-mesenchymal transition

P53-Induced Gene 3 Mediates Cell Death Induced by Glutathione Peroxidase 3*

Apoptotic and DNA Damage Effect of 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose in Cisplatin-Resistant Non-Small Lung Cancer Cells via Phosphorylation of H2AX, CHK2 and p53

Lipophilic Grape Seed Proanthocyanidin Exerts Anti-Proliferative and Pro-Apoptotic Effects on PC3 Human Prostate Cancer Cells and Suppresses PC3 Xenograft Tumor Growth in Vivo.

Pentagalloylglucose disrupts the PALB2-BRCA2 interaction and potentiates tumor sensitivity to PARP inhibitor and radiotherapy

Β-Pentagalloyl-glucose Sabotages Pancreatic Cancer Cells and Ameliorates Cachexia in Tumor-Bearing Mice

Network Pharmacology and Molecular Docking Identify Mechanisms of Medicinal Plant-Derived 1,2,3,4,6-Penta-o-galloyl-beta-d-glucose Treating Gastric Cancer

(-)-Gossypol Suppresses the Growth of Human Prostate Cancer Xenografts Via Modulating Vegf Signaling-Mediated Angiogenesis

Investigation of the inhibition effect of 1,2,3,4,6-pentagalloyl-β-D-glucose on gastric cancer cells based on a network pharmacology approach and experimental validation